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infection rate (23.3 vs. 3.8%; p = 0.002) and insufficiency of 
the duodenal stump (13.3 vs. 1.9%; p = 0.022) were signifi-
cantly higher in the CHEMO group.  Conclusion: This study 
showed no significant impact of neoadjuvant chemothera-
py on postoperative morbidity after gastrectomy using the 
Clavien-classification. Only an increase in wound infections 
in CHEMO compared with the SURG group were noted. 
Therefore, neoadjuvant chemotherapy can be considered 
safe and feasible.  © 2015 S. Karger AG, Basel 
 Introduction 
 Despite its declining incidence, gastric cancer is still 
ranked third among the world’s leading cause of cancer 
deaths, affecting approximately 800,000 people annually 
 [1] . Due to a standardized operative approach, surgical 
morbidity and mortality rates are constantly declining, 
but the overall prognosis of stomach cancer still remains 
poor. In the Western world, the five-year overall survival 
rate for all tumor stages is only between 20 and 25%, with 
a median survival time of 24 months. Nowadays, cancer 
of the stomach is treated with stage-adapted therapy 
 [2] . In Europe multimodal treatment, including neoadju-
vant chemotherapy and surgical resection with negative 
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 Abstract 
 Background/Aims: Patients with locally advanced gastric 
cancer benefit from neoadjuvant chemotherapy. Potential 
disadvantages of neoadjuvant chemotherapy include in-
creased surgical complications, leading to increased postop-
erative morbidity.  Methods: We retrospectively studied 
medical records of 135 patients with resectable cancer of the 
stomach who underwent gastrectomy between 2002 and 
2009. The impact of neoadjuvant chemotherapy on postop-
erative morbidity was investigated. We compared demo-
graphic, clinical and operative data, morbidity and mortality 
from 105 patients who received surgical treatment immedi-
ately after diagnosis (SURG group), versus 30 patients who 
first received neoadjuvant chemotherapy  (CHEMO group). 
 Results: Demographic, clinical and surgical procedure pa-
rameters did not differ significantly between both groups. 
Postoperative morbidity was 46.7% in CHEMO- and 41.9% in 
SURG-patients (p = 0.680). There were eight cases of death, 
2/30 (6.7%) in CHEMO and 6/105 (5.7%) in the SURG group 
(p = 1). The overall complications according to Clavien-clas-
sification did not differ significantly (p = 0.455). The wound 
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margins (R0-resection), is considered to be the standard 
treatment of gastric cancer  [3, 4] . Several trials demon-
strated a statistically significant increase in disease-free 
and overall survival in patients treated with perioperative 
chemotherapy  [5, 6] . One question that still remains un-
answered is whether the neoadjuvant use of chemothera-
py has a negative influence on the postoperative course of 
the patients and therefore could increase the postopera-
tive morbidity after gastrectomy  [7–14] . In previous trials 
regarding the use of neoadjuvant chemotherapy in gastric 
cancer, the efficacy and feasibility of chemotherapy is de-
scribed in particular. Most of the research conducted ear-
lier focused on the adverse effects of chemotherapy before 
gastrectomy, and the effect in correlation with the follow-
ing resection is often only generally  [5, 6, 15] . Other stud-
ies providing this information have not included a com-
parative group of patients who solely underwent surgery 
 [16–21] .
 The aim of this retrospective study was to investigate, 
in a retrospective parallel group, the influence of neoad-
juvant chemotherapy on the postoperative morbidity af-
ter gastrectomy in patients with gastric cancer.
 Patients and Methods 
 Patients’ medical records and histological data during the pe-
riod from June 2002 to December 2009 were retrospectively stud-
ied. The 135 patients included in this study had histologically prov-
en gastric cancer and they received gastrectomy with curative 
 intent, including D2 lymph node dissection at the Department of 
General and Visceral Surgery, Goethe University, Frankfurt. One 
hundred and five patients underwent surgical treatment immedi-
ately after diagnosis (SURG group) and 30 patients were treated 
with neoadjuvant chemotherapy first (CHEMO group). This treat-
ment was decided by a multidisciplinary tumour conference. 
 Information regarding postoperative morbidity and mortality 
were available for each patient studied. Postoperative complica-
tions were considered in addition to lethal outcomes that occurred 
during hospital stay. In addition to morbidity, all postoperative 
complications were graded according to the Clavien-classification 
 [22] .
 Patients received total, remnant or distal gastrectomy, depend-
ing on the anatomic location of the tumour, to achieve R0-resec-
tion. Multivisceral resection was performed when necessary. All 
received a preoperative single-shot antibiotic prophylaxis. Recon-
struction of the gastrointestinal passage was performed accord-
ing to the local standard using a long Roux-en-Y loop. Esophago-
jejunostomy was performed with a 25 mm circular stapler, and 
gastrojejunostomy was hand sewn. A D2 lymphadenectomy was 
performed in all patients according to the guidelines of the 
 Japanese Gastric Cancer Association. Pathological data was anal-
ysed by the Senckenberg Institute for Pathology of Goethe Uni-
versity, Frankfurt, according to the 6th TNM-classification from 
2002  [23] .
 Demographic, clinical, operative and pathological characteris-
tics as well as postoperative complications of the two groups were 
analysed. Statistical analysis was performed with SPSS 21.0 statisti-
cal software. The comparisons among the groups were performed 
with Fisher’s test, t-test and Mann-Whitney U test. p values  ≤ 0.05 
were considered to be significant.
 Results 
 Preoperative Staging and Neoadjuvant Chemotherapy 
Regimens 
 For staging, patients routinely underwent gastroscopy, 
endoscopic ultrasound (EUS), and chest and abdominal 
CT scan. Diagnostic staging laparoscopy was performed 
in 6 patients to exclude peritoneal carcinosis. All had neg-
ative results.
 Patients within the CHEMO group received their neo-
adjuvant chemotherapy with different regimens, mainly 
ECF (Epirubicin, Cisplatin, Fluorouracil), ECX (Epirubi-
cin, Cisplatin, Capecitabine), EOX (Epirubicin, Oxalipla-
tin, Capecitabine) and PLF (Cisplatin, Leucovorin ® , Flu-
orouracil) courses, in standard doses  [5, 24, 25] . Two 
(6.7%) could not be assigned to one of the four above-
mentioned courses and received their chemotherapy ac-
cording to the FOLFOX and FOLFIRI regimens. None of 
them received radiation therapy. 68.7% received all 
planned courses. In four cases chemotherapy had to be 
discontinued, all involving the ECX course. Reasons were 
renal toxicity (Cisplatin), anaemia (5-FU), neutropenia 
(5-FU) and in one case unknown.
 Patient Demographic and Pathological Characteristics 
 The average age for the entire group was 64.8.  CHEMO 
patients tended to be slightly younger (61.7 vs. 65.6 
years). The entire group included 83 men, with slightly 
more men within the CHEMO group (70.0 vs. 59.0%). 
The BMI value for the whole group was 24.9 kg/m 2 (15.6–
35.6). The median ASA status (American Society of An-
esthesiologists) was three in both groups (1–4). Within 
the two groups, 20.0% (CHEMO) versus 14.3% (SURG) 
of patients had diabetes mellitus. CHEMO and SURG 
groups did not differ significantly for one of the above-
mentioned parameters. Patient demographics are sum-
marized in  table 1 .
 Pathological characteristics are outlined in  table  2 . 
SURG patients were more likely to have proximal 
 tumours, with 35.2% being located at the cardia com-
pared to 30.0% in the CHEMO group (p = 0.667). Con-
versely, CHEMO patients were more likely to have lesions 
in the middle and distal part of the stomach (p = 0.361 
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and p = 0.484). Gastric remnant cancer occurred only 
within the SURG group (9.5%; p = 0.118). Two patients 
in the SURG group did not suffer from an adenocarci-
noma of the stomach, but had a squamous cell and undif-
ferentiated carcinoma. According to the postoperative 
UICC (Union for International Cancer Control) classifi-
cation (6th TNM classification from 2002), the two groups 
did not differ significantly.
 Operative Parameters 
 The mean total operating time was 236.0 min in 
 CHEMO and 243.9 min in the SURG group (p = 0.589). 
The median blood loss was 400 ml in both groups. Peri-
operative transfusion was accomplished in 30.0% of 
CHEMO and 29.5% of SURG patients. CHEMO patients 
(90.0%) had more total gastrectomies than the SURG 
group (79.0%) (p = 0.285), and only in the SURG group 
was a resection of the gastric remnant was performed 
(p = 0.118). In total, 56 (41.5%) patients underwent tran-
shiatal extended gastrectomy, 43.3 in the  CHEMO and 
40.9 in the SURG group. Complete resection (R0) was 
achieved in 90.0% of CHEMO and in 90.5% of SURG pa-
tients (p = 0.711). The median number of dissected lymph 
nodes did not differ significantly in both groups, 30 with 
chemotherapy (14–71) vs. 23 (8–56) with surgery alone, 
as well as positive lymph node ratio with 4.5% (0–70) and 
11.0% (0–100) (p = 0.686). Multivisceral resection includ-
ing splenectomy due to oncological or technical reasons, 
partial pancreatectomy, partial colectomy and partial liv-
er resection was performed in 10.0% of CHEMO patients, 
compared to 10.5% of SURG patients (p = 1). Operative 
parameters are shown in  table 3 . Surgery was performed 
within the median of 37.5 days (10–79) after the last day 
of chemotherapy.
 Postoperative Complications 
 Postoperative complications occurred in 58 (43.0%) of 
the 135 patients. Both groups did not differ significantly 
(46.7% in CHEMO and 41.9% in the SURG group; 
p  =  0.680;  table  4 ). The median postoperative hospital 
stay was 13.5 days in CHEMO and 15.0 days in the SURG 
group. For patients without complications and for those 
suffering from complications, the median of postopera-
tive stay did not differ significantly in either group 
(p = 0.284 and p = 0.052).
 A nosocomial infection was the most commonly ob-
served postoperative complication, with an average rate 
of 29.6% (43.3% in CHEMO and 25.7% in the SURG 
group; p = 0.073). In declining order, urinary tract infec-
tions, pneumonia, wound infections and intra-abdomi-
nal infections occurred. Significantly more wound infec-
tions could be noted in the CHEMO group (23.3 vs. 3.8%; 
p = 0.002). A leakage of the esophagogojejunostomy was 
the second most commonly observed complication 
(11.1%), 3.3% in CHEMO and 13.3% in the SURG group 
Table 1.  Patient demographics and clinical data
CHEMO (%)
(n = 30)
SURG (%)
(n = 105)
p 
value
Age, years 0.123
Mean ± SD 61.7±9.7 65.6±12.8
Range 37–75 22–92
Gender 0.298
Male 21 (70.0) 62 (59.0)
Female 9 (30.0) 43 (41.0)
BMI, kg/m2 0.689
Mean ± SD 24.6±3.8 24.9±4.0
Range 15.6–35.6 17.5–33.0
ASA status, median 3 3 0.917
1 2 (6.7) 8 (7.6) 1
2 9 (30.0) 30 (28.6)
3 17 (56.7) 58 (55.2)
4 1 (3.3) 3 (2.9)
X 1 (3.3) 6 (5.7)
Comorbidities
Diabetes mellitus 6 (20.0) 15 (14.3) 0.568
Chronic infectious disease 1 (3.3) 6 (5.7) 1
 X = Missing data; chronic infections = chronic viral hepatitis and 
HIV infections.
Table 2.  Pathological findings
CHEMO (%)
(n = 30)
SURG (%)
(n = 105)
p 
value
Type of tumour
Adenocarcinoma 30 (100) 103 (98.2) 1
Other 0 (0) 2 (1.8) 1
Tumour location
Proximal part 9 (30.0) 37 (35.2) 0.667
Middle part 11 (36.7) 28 (26.7) 0.361
Distal part 9 (30.0) 25 (23.8) 0.484
Entire stomach 1 (3.3) 5 (4.8) 1
Remnant cancer 0 (0) 10 (9.5) 0.118
UICC
Stage 0 0 (0) 2 (1.9) 1
Stage IA 4 (13.3) 19 (18.1) 0.783
Stage IB 4 (13.3) 19 (18.1) 0.783
Stage II 8 (26.7) 18 (17.1) 0.294
Stage IIIA 4 (13.3) 15 (14.3) 1
Stage IIIB 5 (16.7) 16 (15.2) 0.783
Stage IV 5 (16.7) 16 (15.2) 0.783
 UICC = Union for International Cancer Control.
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(p = 0.189). A leakage of the duodenal stump occurred 
less frequently, in 13.3% (CHEMO), and 1.9% (SURG). 
Only the rate of insufficiency of the duodenal stump dif-
fered significantly (p = 0.022). The one anastomotic leak-
age in CHEMO was treated conservatively. In the SURG 
group, the anastomotic dehiscence was treated in 6/14 
(42.8%) cases by reoperation, in 4/14 (28.6%) cases con-
servatively, in 2/14 (14.3%) cases by interventional radi-
ology, and in 2/14 (14.3%) cases by endoscopy. During 
the six reexplorations in 4/6 (66.7%) cases, the esophago-
jejunostomy was sutured, and in 2/6 (33.3%) cases, a new 
anostomosis was constructed. The four leakages of the 
duodenal stump in the CHEMO group were treated in 
3/4 (75.0%) cases by reexploration with suture and could 
be managed in 1/4 (25.0%) cases conservatively. In the 
SURG group, the two patients were treated by reopera-
tion (50.0%) and conservatively (50.0%). Other compli-
cations were internal hernias, one in each group, and a 
perforation of the jejunum simultaneously with the 
stomach (CHEMO group). All three cases were reex-
plored. A reexploration had to be performed in 14.1% of 
all patients. Neither group did differ significantly (16.7 
vs. 13.3%; p = 0.766). The most common causes for re-
operation were intra-abdominal bleeding, explorative 
laparotomy to rule out peritonitis, and anastomotic leak-
age.
 Postoperative mortality was 6.7% in CHEMO and 
5.7% in SURG patients (p = 1). Both cases of death in the 
CHEMO group were the result of multi-organ failure due 
to sepsis. In one case, an anastomotic leakage was the rea-
Table 3.  Patient operative parameters
CHEMO (%) 
(n = 30)
SURG (%) 
(n = 105)
p value
Total operative time, min 0.589
Mean ± SD 243.9±74.0 236.0±69.5
Range 135–461 80–435
Operative blood loss, ml 1
Median 400 400
Range 100–2,000 100–2,800
Patients with transfusion 9 (30.0) 31 (29.5) 1
Type of resection 0.198
Total 27 (90.0) 83 (79.0) 0.285
Partial distal 3 (10.0) 12 (11.4) 1
Gastric remnant resection 0 (0) 10 (9.5) 0.118
Extent of resection
R0 27 (90.0) 95 (90.5) 0.711
R1/2 3 (10.0) 8 (7.6) 0.711
Missing 0 (0) 2 (1.9)
Number of resected lymph nodes 0.638
Median 30 23
Range 14–71 8–56
Lymph node ratio, positive LN/total LN, % (range) 4.5 (0–70) 11.0 (0–100) 0.686
Patient with multivisceral resection 3 (10.0) 11 (10.5) 1
Spleen 2 (6.7) 9 (8.6) 1
Oncological 2 (6.7) 8 (8.6) 1
Technical 0 (0) 1 (1.0) 1
Pancreas 2 (6.7) 8 (7.6) 1
Colon 2 (6.7) 2 (1.9) 0.214
Liver 1 (3.3) 1 (1.0) 0.396
Reconstruction
Y-Roux 29 (96.7) 100 (95.2) 1
Other 1 (3.3) 5 (4.8)
Stapler 27 (90.0) 93 (88.6) 1
Hand sewn 3 (10.0) 12 (11.4)
 LN = Lymph node.
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son for sepsis, and in the second case, a cardiac arrest of 
a 75-year multimorbid old man, with myocardial re-in-
farction and preexisting renal failure. Three of six cases 
of death (50.0%) in the SURG group were caused by re-
spiratory insufficiency caused by an anastomotic leakage. 
Two patients (33.3%) died due to diffuse bleeding that 
could not be stopped by operation. In one case (16.7%), 
multiorgan failure due to sepsis was caused by an anas-
tomotic leakage. The median interval between operation 
and death was 19.0 days (17–21) in the  CHEMO group 
and 18.0 days (8–36) in the SURG group (p = 0.867). Re-
garding the entire Clavien-classifcation, the two groups 
did not differ significantly, with 73.3% in the CHEMO 
group and 80.0% in the SURG group (p = 0.455;  table 5 ).
 Discussion 
 In the Western world, most gastric cancers are diag-
nosed in advanced stages because of unspecific symp-
toms  [26] . The goal of surgery for gastric cancer is a cu-
rative resection, with the removal of all gross tumour 
and regional lymph nodes. Because of the improve-
ments in staging and the increase of knowledge about 
the value of neoadjuvant strategies, multimodal therapy 
in the treatment of gastric cancer is gaining more and 
more importance. Two pioneering studies showed a sig-
nificant increase of disease-free and overall survival rate 
in a direct randomised comparison of patients with lo-
cally advanced adenocarcinoma of the stomach or lower 
Table 4.  Morbidity and mortality
CHEMO (%)
(n = 30)
SURG (%)
(n = 105)
p value
Postoperative LOS, days 0.184
Median 13.5 15.0
Range 8–90 7–91
Postoperative morbidity (any complication) 14 (46.7) 44 (41.9) 0.680
Postoperative infection 13 (43.3) 27 (25.7) 0.073
Urinary tract infection 5 (16.7) 11 (10.5) 0.349
Pneumonia 3 (10.0) 10 (9.5) 1
Wound infection 7 (23.3) 4 (3.8) 0.002*
Intra-abdominal abscess 1 (3.3) 2 (1.9) 0.533
Anastomotic dehiscence (esophagojejunostomy) 1 (3.3) 14 (13.3) 0.189
Postoperative haemorrhage 3 (10.0) 7 (6.7) 0.692
Duodenal stump leakage 4 (13.3) 2 (1.9) 0.022*
Fascial dehiscence 1 (3.3) 2 (1.9) 0.533
Anastomotic dehiscence (jejunojejunostomy) 1 (3.3) 1 (1.0) 0.396
Other postoperative complication 2 (6.7) 1 (1.0) 0.124
Relaparotomy 5 (16.7) 14 (13.3) 0.766
Hospital mortality 2 (6.7) 6 (5.7) 1
 LOS = Length of stay. * p ≤ 0.05.
Table 5.  Severity of complications according to Clavien-classification in the two groups
CHEMO (%)
(n = 30)
SURG (%)
(n = 105)
p value
Clavien-classification (any complication) 22 (73.3) 84 (80.0) 0.455
Grade I 0 (0) 4 (3.8) 0.578
Grade II 10 (33.3) 41 (39.0) 0.815
Grade III 6 (20.0) 25 (23.8) 1
Grade IV 4 (13.3) 8 (7.6) 0.267
Grade V 2 (6.7) 6 (5.7) 0.670
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esophagus treated with perioperative chemotherapy and 
surgery, compared to those who solely underwent sur-
gery  [5, 6] . Besides that, a possible theoretical advantage 
of neoadjuvant chemotherapy is that blood vessels, 
which may be important for the chemotherapy local 
drug delivery, are not altered by surgery. Thus, neoad-
juvant chemotherapy offers the possibility of an in vivo 
testing of the therapy applied, and micrometastasis can 
be treated. Due to the better condition of patients in pre-
operative administration of chemotherapy compared to 
the postoperative approach, a higher concentration of 
chemotherapeutics can be administered, and compli-
ance as well as tolerability are usually better in the pre-
operative neoadjuvant setting. Furthermore, in more 
advanced stages, a higher complete R0-resection rate 
could be achieved and therefore, a positive influence on 
overall survival  [27–29] . Essential problems of neoadju-
vant chemotherapy are the possible impact on wound 
healing and immunocompetence. In animal studies on 
Cisplatin, a negative influence on wound healing was 
demonstrated. In these rodent studies, a reduced prolif-
eration of fibroblasts, a decline of tissue proliferation 
and an inhibition of neovascularisation occurred  [12] . 
In addition, a reduction of bursting pressure resistance 
of intra-abdominal anastomosis was noted  [7, 8] . In rats, 
the administration of a high perioperative dose of 5-FU 
led to a decrease in wound tensile strength. Animal ex-
periments on 5-FU also showed a decline of the strength 
of visceral anastomosis, especially in the early postop-
erative phase  [9–11, 13, 14] . As a result, a higher rate of 
postoperative complications could occur. In previous 
trials on the use of neoadjuvant chemotherapy in gastric 
cancer, the efficacy and feasibility of chemotherapy are 
described in detail. Most preceding research focused on 
the acute toxicity and adverse effects of chemotherapy 
before gastrectomy, and the effect in correlation with the 
following resection is often only generally measured  [5, 
6, 15] . Other studies providing this information have 
not included a comparative group of patients who sole-
ly underwent surgery  [16–20] .
 Multimodal treatment in the therapy of gastric cancer 
gained consideration because of the pioneering results of 
the MAGIC trial, published in 2006  [5] . Patients included 
in our study were treated between June 2002 and 
 December 2009. As mentioned above, the decision about 
treatment and allocation to the CHEMO or the SURG 
group, was decided by a multidisciplinary tumour confer-
ence. UICC stages were collected postoperatively on the 
resected specimens. 53.3% of patients within the  CHEMO 
group had postoperative UICC stages I and II, and he 
proportion of ypT0/1/2 tumour-stage was 70.0%. There-
fore, we assume that a downstaging due to neoadjuvant 
chemotherapy occurred. Based on the German S3-guide-
line ‘Diagnosis and Treatment of Esophagogastric Can-
cer’, published in 2011, from UICC stage IIIA and tu-
mour stage uT3 (endoscopic ultrasound), neoadjuvant 
chemotherapy should be administered. For stages IB, II 
and uT2, a neoadjuvant therapy is ‘possible’  [2] . In con-
clusion, around the time of our study, guidelines incor-
porated the concept of neoadjuvant chemotherapy and 
thus, the decision to treat patients with neoadjuvant che-
motherapy was made more broadly.
 Age, BMI and gender are considered possible risk 
 factors for postoperative complications  [30–33] . The 
 CHEMO and SURG groups did not differ significantly 
for one of these parameters ( table 1 ). Likewise, the two 
groups also did not differ significantly in their UICC stag-
es and operative parameters ( tables 2 and  3 ). Therefore, 
despite the limits of a retrospective study, it seems justi-
fied to explore the influence of neoadjuvant chemothera-
py on postoperative morbidity with this design. Our pa-
tients’ demographics are comparable to other studies. In 
a study by Ychou et al.  [6] , the median age was 63, and 62 
in a study of Cunningham et al.  [5] . The average BMI was 
23 kg/m 2 in a comparable study  [34] . In contrast, our pa-
tients tended to be slightly older and their average BMI 
was a bit higher. In studies by Siewert et al.  [35] and Ott 
et al.  [25] , 60.0% of all patients were male.
 The most frequent complications following gastrec-
tomy are surgical site infections, such as wound infec-
tions and intra-abdominal abscess, as well as a leakage 
of the esophagogojejunostomy  [35–44] . Postoperative 
morbidity after gastric cancer resection ranges between 
7.7%  [35] and 57.9%  [45] , and mortality between 0.0% 
 [25, 34, 46–48] up to 13.0%  [49] . It should be noted that 
there is, in general, a problem in the comparability of 
postoperative morbidity of different studies: the criteria 
of postoperative morbidity either were not outlined  [5, 
6, 25, 49–54] or different criteria were included  [15–20, 
34, 35, 45, 46, 55–61] . For this reason, we used the Cla-
vien-classification to compare the two groups. In our 
study, we could not observe a significant influence of 
neoadjuvant chemotherapy on postoperative complica-
tions using Clavien-classification ( table 5 ). We abstained 
from dividing the groups in rank IIIa/b and IVa/b in 
Clavien-classification because of the small number of 
cases.
 Postoperative morbidity was 46.7% in CHEMO and 
41.9% in the SURG group, and postoperative mortality 
was 6.7 and 5.7%, respectively. Neither group differed 
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 significantly ( table 4 ). Our results are in accordance with 
the results of two big randomised controlled trials: that 
the use of neoadjuvant chemotherapy in treatment of 
 gastric cancer has no significant negative influence on 
postoperative morbidity after gastrectomy  [5, 6] . In the 
 MAGIC trial, postoperative morbidity in the CHEMO 
and SURG groups was 45.7 and 45.3%, respectively, and 
mortality was 5.6 vs. 5.9%. In these two trials, a detailed 
analysis of the observed postoperative complications was 
missing, as emphasis was placed on the oncological out-
come.
 In our study, nosocomial infection (29.6%) was the 
most commonly observed postoperative complication 
( table 4 ). The wound infection rate differed significant-
ly between the two groups, with 23.3% in CHEMO and 
3.8% in the SURG group (p = 0.002). This difference 
may be caused by neoadjuvant chemotherapy. An anas-
tomotic leakage (11.1%) was the second most common-
ly observed complication. A leakage of the duodenal 
stump occurred in 13.3% in the CHEMO group and in 
1.9% in the SURG group. This incidence showed a sig-
nificant difference (p = 0.022). According to the differ-
ent results concerning the number of leakages of the 
anastomosis and the duodenal stump, no clear correla-
tion to the neoadjuvant chemotherapy can be drawn in 
this patient cohort. The observed mismatch may be 
caused by technical differences or just by chance and the 
relatively low number of patients. Technical aspects of 
closing the duodenal stump were not possible to be con-
sidered in this retrospective analysis. The third most 
frequently observed complication was postoperative 
bleeding (8.1%) (p = 0.692). A reoperation was neces-
sary in 14.1% of the patients and neither group differed 
significantly (p = 0.766). The most common indications 
for reoperation were intra-abdominal bleeding, explor-
ative laparotomy to rule out peritonitis, and anastomot-
ic leakage. 
 Conclusion 
 In conclusion, according to this study, the use of neo-
adjuvant chemotherapy in the operative therapy of gas-
tric cancer does not significantly increase the rate of post-
operative morbidity using the Clavien-classification. 
Only an increase of wound infections in the CHEMO 
group compared with the SURG group was noted. There-
fore, neoadjuvant chemotherapy can be considered safe 
and feasible.
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